Zum Hauptinhalt springen
Hochschulbibliothek Niederrhein

Suchergebnisse

Katalog

Mehr
69 Treffer

Suchmaske

Suchtipp für den Bereich Mehr: Wörter werden automatisch mit UND verknüpft. Eine ODER-Verknüpfung erreicht man mit dem Zeichen "|", eine NICHT-Verknüpfung mit einem "-" (Minus) vor einem Wort. Anführungszeichen ermöglichen eine Phrasensuche.
Beispiele: (burg | schloss) -mittelalter, "berufliche bildung"

Suchergebnisse einschränken oder erweitern

Aktive Suchfilter

Erscheinungszeitraum

Mehr Treffer

Weniger Treffer

Art der Quelle

Thema

Verlag

Sprache

Inhaltsanbieter

69 Treffer

Sortierung: 
  1. Detailansicht für Treffer 1 öffnen
    Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  2. Detailansicht für Treffer 2 öffnen
    A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  3. Detailansicht für Treffer 3 öffnen
    Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
    Active Biotech, AB
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  4. Detailansicht für Treffer 4 öffnen
    A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  5. Detailansicht für Treffer 5 öffnen
    Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis. (BioPredictor)
    University Hospital, Brest ; Nantes University Hospital ; et al.
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  6. Detailansicht für Treffer 6 öffnen
    Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia
    Zhang Lei, MD, Professor/Vice director of Thrombosis &Hemostasis Center
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  7. Detailansicht für Treffer 7 öffnen
    Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  8. Detailansicht für Treffer 8 öffnen
    Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  9. Detailansicht für Treffer 9 öffnen
    An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  10. Detailansicht für Treffer 10 öffnen
    A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  11. Detailansicht für Treffer 11 öffnen
    Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance (SURPASS ET)
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  12. Detailansicht für Treffer 12 öffnen
    IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
    Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) ; Terrence J Bradley, MD, Assistant Professor
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  13. Detailansicht für Treffer 13 öffnen
    Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  14. Detailansicht für Treffer 14 öffnen
    Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia
    Zhang Lei, MD, Professor/Vice director of Thrombosis &Hemostasis Center
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  15. Detailansicht für Treffer 15 öffnen
    Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2
    Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  16. Detailansicht für Treffer 16 öffnen
    PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
    National Cancer Institute (NCI)
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  17. Detailansicht für Treffer 17 öffnen
    CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia
    National Cancer Institute (NCI)
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  18. Detailansicht für Treffer 18 öffnen
    An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)
    Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  19. Detailansicht für Treffer 19 öffnen
    Arterial Function and Atherosclerosis in Essential Thrombocythemia
    Ales Blinc, Ales Blinc, MD, PhD, Head, Dept of Vascular Diseases
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
  20. Detailansicht für Treffer 20 öffnen
    A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)
    Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
    Online report
    Zugriff:
    View record at ClinicalTrials.gov (Volltext)
    Wie komme ich dran?
xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -